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Abstract. Little is known about the fate of machinery
proteins of the protein quality control and endoplas-
mic reticulum (ER)-associated degradation (ERAD).
We investigated the degradation of the ERAD
component EDEM1, which directs overexpressed
misfolded glycoproteins to degradation. Endogenous
EDEM1 was studied since EDEM1 overexpression
not only resulted in inappropriate occurrence
throughout the ER but also caused cytotoxic effects.
Proteasome inhibitors had no effect on the clearance
of endogenous EDEM1 in non-starved cells. How-
ever, EDEM1 could be detected by immunocyto-
chemistry in autophagosomes and biochemically in
LC3 immuno-purified autophagosomes. Further-
more, influencing the lysosome-autophagy pathway
by vinblastine or pepstatin A/E64d and inhibiting
autophagosome formation by 3-methyladenine or
ATGs short interfering RNA knockdown stabilized
EDEM1. Autophagic degradation involved removal
of cytosolic Triton X-100-insoluble deglycosylated
EDEM1, but not of EDEM1-containingER cisternae.
Our studies demonstrate that endogenous EDEM1 in
cells not stressed by the expression of a transgenic
misfolded protein reaches the cytosol and is degraded
by basal autophagy.
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Introduction
The conformation of glycoproteins in the early
secretory pathway is monitored by a quality control
machinery [1, 2]. Non-native glycoprotein conformers
are retained in the endoplasmic reticulum (ER)where
they are exposed to the protein folding machinery.
Terminally misfolded glycoproteins and excess sub-
units of heteromeric proteins are targeted for degra-
dation by a process named ER-associated protein
degradation (ERAD) [3, 4].
EDEM1 (ERdegradation-enhancinga-mannosidase-
like protein) and its yeast homologue Htmp1p are
ERAD components that associate with ERAD sub-
strates such as the Hong Kong variant of a1-antitryp-
sin [5–7]. It links the calnexin cycle to ERAD since
EDEM1 overexpression caused accelerated release of
mutant glycoproteins from calnexin and enhanced
their clearance [6, 8, 9]. In addition, EDEM1 has been
shown to interact with non-ERAD substrates such as
endocytozed ricin and to be involved in its dislocation
from the ER to the cytosol [10]. EDEM1 associates
with Derlin-2 or -3 [11], two integral membrane
proteins, which have beenproposed to formpart of the
dislocation machinery for ERAD [12, 13]. These data
indicate that EDEM1 is an ERAD component that is
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mainly involved in the transport of glycosylated
ERAD substrates out of the ER [6, 8, 9, 14]. This is
followed by their de-glycosylation by the cytosolic
peptide:N-glycanase [15, 16] and degradation.
The degradation pathway of ERAD machinery pro-
teins themselves, including that of EDEM1 [17], is
poorly understood. However, EDEM1 has to be
tightly regulated in the ER since otherwise all
glycoproteins with mannose-trimmed N-glycans po-
tentially would become EDEM1 substrates [5–7] in
an indiscriminatemanner andwould be retained in the
ER. This presumptive regulation is supported by our
observation of the strikingly different subcellular
distribution between endogenous and overexpressed
EDEM1 [14]. Endogenous EDEM1, even in cells
overexpressing the Hong Kong variant of a1-anti-
trypsin, is mostly present in ER-derived vesicles and
the cytosol, whereas overexpressed EDEM1 is addi-
tionally detected throughout the entire ER.
Twomain cellular degradative pathways are known to
exist: the proteasomes and the lysosome-autophagy
system. Proteasomes degrade polyubiquitin-tagged
proteins after they have been unfolded by the
proteasomal 19S cap [18]. Autophagy is the process
that results in the lysosomal degradation of the cells
own constituents such as part of the cytoplasm (so-
called macroautophagy) and organelles [19]. Basal
autophagy is an important regulatory process through
which the constitutive turnover of organelles and
cytoplasmic proteins is accomplished. This was un-
equivocally shown in tissue-specific autophagy knock-
out mice [20–22]. Autophagy is not only an important
cellular degradation mechanism [23], but also plays
active roles in development, cancer and immune
defense, and is a pre-condition for apoptosis [24–
27]. Once autophagosomes are formed through the
concerted action of differentATGgene products, they
quickly fuse with lysosomes [28]. Autophagy can be
induced or blocked by amino acid starvation or be
triggered by ER stress enabling cells to return to
regular metabolic states [29–31].
Using a combination of morphological and biochem-
ical approaches, we show that endogenous EDEM1 in
the cytosol, in the absence of induced cellular stress, is
degraded by basal autophagy, and that overexpression
of EDEM1 evokes cytotoxic effects. Thus, basal
autophagy is involved in the degradation of EDEM1
by removing it from the cytosol.
Materials and methods
Cell culture and transient transfection.HepG2, HeLa
and HEK293 cells (obtained from ATCC, Manassas,
VA) were grown on glass coverslips to 25% conflu-
ency in MEM (Eagle, Gibco, Auckland, NZ) supple-
mented with 10% fetal bovine serum (FBS, Gibco)
and 1.0 mM sodium pyruvate (Gibco) at 378C in a
humidified atmosphere of 5% CO2. For transfection,
cells were washed in Opti-MEM I (Invitrogen, Carls-
bad, CA) and transfected for 5 h using FUGENEHD
or FUGENE 6 (Roche Diagnostics, Mannheim,
Germany; lipid/plasmid DNA ratio of 6:2). Each cell
typewas transfectedwith amixture of CMV-EDEM1-
p3xFLAG vector and pEGFP-C1-rat-endomannosi-
dase-CMV vector [32] or with CMV-p3xFLAG con-
trol vector and pEGFP-C1-rat-endomannosidase-
CMV vector at a ratio of 10:1. Cells were analyzed
by immunofluorescence immediately following trans-
fection or 1, 3 or 7 days after transfection to assess
gene expression and cell morphology. Before fixation,
cells were stainedwithHoechst 33342. Formaldehyde-
fixed cells (see below) were incubated with mouse
monoclonal anti-FLAG antibody (M2, Sigma) fol-
lowed by RedX-conjugated goat anti-mouse IgG
(Jackson ImmunoResearch Laboratories, West
Grove, PA) and examined by epifluorescence micro-
scopy (Zeiss Axioplan microscope; 40 objective,
1.3).
Short interfering RNA (siRNA) transfection. Dou-
ble-stranded siRNA targeting human ATG5, ATG7
and ATG12 were purchased from Invitrogen (Carls-
bad, CA). HepG2 cells were transfected with ATG
siRNAs with Metafectene reagent according to man-
ufacturers instructions (Biontex Laboratories, Ger-
many). In brief, 80 nM siRNA and Metafectene
reagent was mixed with Opti-MEM I reduced serum
medium and incubated for 20 min at ambient temper-
ature. Afterwards, the mixture was added to freshly
trypsinized HepG2 cells (2105) in serum-free me-
dium and incubated 5 h before addition of 10% FBS.
At 48 h post transfection, cells were used for pulse-
chase experiments or Western blotting.
RT-PCR. Cellular mRNA was isolated using a First
Strand cDNA Synthesis kit (Roche) according to the
manufacturers instructions. Serial dilutions of
cDNAs were subjected to PCR amplification of
EDEM1. GAPDH and actin served as internal stand-
ards. PCR products were resolved in 1% agarose gels.
Pulse chase and immunoprecipitation. Cells grown to
70–80% confluency were fed with fresh medium 16 h
before metabolic labeling. In the pulse-chase experi-
ments, cells were rinsed quickly once in methionine-
and cysteine-free MEM (Sigma), pulsed for 20 min
with [35S]methionine-cysteine (120 mCi/ml; NEN,
Boston, MA) in methionine- and cysteine-free
MEM, washed four times in complete medium and
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chased in complete medium supplemented with 4 mM
of both methionine and cysteine. For proteasome
inhibition, cells were chased in the presence of 1 mM
epoxomycin (Sigma), 20 mM MG 132 (Calbiochem,
San Diego, CA) or 100 mMALLN (Calbiochem); for
autophagosome accumulation, in the presence of
50 mM vinblastine (Sigma); for inhibition of autopha-
gosome formation with 10 mM 3-methyladenin
(Sigma); and for lysosomal protease inhibition in the
presence of 10 mg/ml of pepstatinAandE64d (Sigma).
For preparation of cell lysates, cells weremechanically
removed, centrifuged and resuspended in lysis buffer
[10 mM phosphate buffer, pH 7.4, containing 1%
Triton X-100 and protease inhibitor cocktail (Roche
Diagnostics)] for 30 min on ice. For immunoprecipi-
tation of endogenous EDEM1, lysates were incubated
overnight at 48C with protein A-Dynal magnetic
beads (Invitrogen, Dynal AS, Oslo, Norway) pre-
coated with Fc-fragment-specific affinity-purified
rabbit anti-goat IgG (Jackson ImmunoResearch Lab-
oratories) and goat anti-human EDEM1 antibody (C-
19, Santa Cruz Biotechnology, Santa Cruz, CA).
Immunoprecipitates were washed four times with
PBS containing 0.5%TritonX-100, boiled in Laemmli
buffer for 5 min, resolved by SDS-PAGE and sub-
jected to autoradiography. Densitometric quantifica-
tion of EDEM1 bands was performed using Image
Quant TL software (GE Healthcare, Bio-Science) or
ImageJ 1.38r (http://rsb.info.nih.gov/ij). Percentage of
degradation was determined in at least four inde-
pendent experiments. Mean values and standard
deviation were calculated using MS Excel. Standard
errors (n-1) of the mean are shown by bars.
Peptide:N-glycosidase F digestion. Cell extracts or
immunoprecipitated EDEM1 were equilibrated in
PNGase F buffer (50 mM Tris, pH 8, 1% Triton X-
100) and subjected to deglycosylation by PNGase F
(Roche diagnostics, 10 U/ml) for 2 h at 378C.
Western blot. Cells were harvested and lysed in lysis
buffer (PBS) containing 1% Triton X-100 and pro-
tease inhibitor cocktail (RocheDiagnostics).After 30-
min incubation on ice, cells were centrifuged at
10 000 g for 10 min. The supernatant containingTriton
X-100-soluble proteins was collected and the pellet
containing Triton X-100-insoluble proteins was wash-
ed in cold PBS and dissolved by sonication in Laemmli
buffer containing 8 M urea. Samples were boiled for
8 min, 1:10 of Triton X-100-soluble and 1:3 of Triton
X-100-insoluble fractionswere loaded and resolved by
SDS-PAGE. Proteins were blotted onto a nitrocellu-
lose membrane. After blocking in 5% Top Block
(Fluka, Buchs, Switzerland) or 5% non-fat dry milk in
TBS-Tween (20 mM Tris-HCl, pH 7.4, 0.5 M NaCl,
0.1% Tween 20), membranes were analyzed for
different proteins. The following primary antibodies
were used: goat anti-human EDEM1 peptide anti-
body (Santa Cruz, C19, sc-27391; N16, sc-27389, both
300-fold diluted), goat anti-human LC3 antibody
(Santa Cruz, N20, sc-16755, 1:300), rabbit anti-ATG5
antibody (Cell Signaling Technology Inc., 2630,
1:2000), mouse anti-LAMP1 antibody (RDIResearch
Diagnostics, Concord,MA,MCD107) and rabbit anti-
calnexin antibody (Stressgen Bioreagent, SPA-865,
1:2000). After overnight incubation at 48C, each blot
was probed with horseradish peroxidase (HRP)-con-
jugated appropriate secondary antibodies (Jackson
ImmunoResearch Laboratories, 1:30 000). Immunor-
eactive bands were visualized by an ECL system (GE
Healthcare, Bio-Science).
2-D electrophoresis. IPG strips (Immobiline DryStrip
pH 5.3–6.5, GE Healthcare, Sweden) were rehydrat-
ed with rehydration buffer (8 M urea, 2% CHAPS,
2% IPG-buffer, 20 mM DTT) overnight at ambient
temperature. Immunoprecipitated 35S-labeled
EDEM1 was PNGase F digested (see above) and
concentrated in Microcon 30 (Millipore, Billerica,
MA). Protein samples were mixed with sample
preparation buffer (8 M urea, 4% CHAPS, 2% IPG
buffer, 40 mM DTT) and applied at the cathodic end
onto the strips. Isoelectric focusing was performed
using a Multiphore II system (Pharmacia Biothec,
Uppsala, Sweden) according to the manufacturers
instructions (300 V for 10 min, 300 V for 6 h, 3500 V
for 8 h, 3500 V for 18 h). Afterwards, the IPG strips
were incubated in equilibration buffer (8 M urea,
75 mM Tris-HCl pH 8.8, 2% SDS, 0.02% bromophe-
nol blue, 30% glycerol) supplemented withDTT (1%
w/v) for 15 min followed by equilibration buffer
supplemented with iodoacetamide (2.5% w/v) for
15 min, at ambient temperature. Proteins were then
resolved by 8% SDS-PAGE in the second dimension
and dried gels were subjected to autoradiography.
OptiPrep density gradient flotation. Post-nuclear
supernatants from vinblastine-treated cells were pre-
pared by centrifugation (1000 g, 10 min, 48C) of
homogenates (prepared using aTeflon glass homoge-
nizer in 10 mM HEPES pH 7.5 containing 250 mM
sucrose, 1 mM EDTA and protease inhibitor cock-
tail). Supernatant was equilibrated to 35% iodixanol
(OptiPrep, Sigma), overlaid with 25% OptiPrep
solution and covered with homogenization buffer.
After centrifugation (180 000 g, 3 h at 48C), the
microsomal fraction was collected at the OptiPrep-
buffer interface, equilibrated to 35% iodixanol sol-
ution and layered below a 0–30% continuous Opti-
Prep gradient. The gradients were centrifuged in a
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swinging bucket rotor (50 000 g for 18 h at 48C) and
fractions collected. Proteins were resolved by SDS-
PAGE (6–18%), transferred to nitrocellulose mem-
branes and incubated with antibodies against calnexin
(BD Biosciences, Erembodegem, Belgium), LAMP1
(Research Diagnostics Inc., Flanders, NJ), EDEM1
(C-19), and LC3 (N20) overnight at 48C followed by
HRP-conjugated secondary antibodies and visualiza-
tion by ECL.
Immuno-purification of autophagosomes. Microso-
mal fraction of vinblastine-treated cells was prepared
as described above and equilibrated with PBS con-
taining 1 mM EDTA, 0.2% BSA and protease inhib-
itor cocktail. Autophagosomes were immuno-purified
with either rabbit anti-human LC3 antibodies (H50)
or goat anti-human LC3 antibodies (N20) covalently
dithiobis(succinimidyl propionate) (DSP)-cross-
linked to proteinA-Dynalmagnetic beads.As control,
non-immune rabbit or goat serum was covalently
DSP-cross-linked to the beads. The immunoprecipi-
tates were boiled in Laemmli buffer, resolved by SDS-
PAGE (6–18%) and analyzed for EDEM1 or LC3 by
Western blot (see above).
Immunofluorescence. Cells were grown on coverslips
to 60–70% confluency and fed with fresh medium
16 h before fixation. Formaldehyde fixation and
saponin permeabilization as well as antibody incuba-
tions were performed as previously reported [14]. For
single, double and triple immunolabeling goat anti-
human EDEM1, rabbit anti-LC3 (H50) and mouse
monoclonal anti-human LAMP1 (Research Diagnos-
tics Inc.) antibodies were applied followed by fluo-
rescent, not cross-reactive, secondary antibodies.
Immunofluorescence was recorded with Leica con-
focal laser scanning microscopes SP2 or SP5 (Leica,
Wetzlar, Germany) using the 100 objective (1.4). In
double- and triple-immunofluorescence overlays, ef-
fects of z-axis pixel shifts were corrected.
Immunoelectron microscopy. Cells grown to near
confluency were double aldehyde-fixed as described
[14]. Frozen ultrathin sections were prepared accord-
ing to Tokuyasu and immunogold-labeled forEDEM1
as described [14].
Pre-embedding immunoperoxidase labeling for
EDEM1 was performed as described [14] and serial
ultrathin sections were prepared in the plane of the
cell layer.
Results
Overexpression of EDEM1 can be deleterious to
cultured cells.Our previous work [14] has shown that
endogenous EDEM1 in different mammalian cell
types is restricted inside the ER to portions of a few
cisternae. This unexpected observation indicates that
protein levels of EDEM1 in the ER are tightly
regulated and that its uncontrolled overexpression
may be deleterious to cells. To test this, HepG2, HeLa
and HEK293 cells were simultaneously transfected
with EDEM1-FLAG under the control of a CMV
promoter and with EGFP targeted to the Golgi
apparatus by the cytosolic domain of endomannosi-
dase as transfection reporter protein (C1-rat endo-
mannosidase-EGFP; see [32]). Although about 20%
of HepG2 cells expressed EDEM1-FLAG/Golgi-
EGFP after a 5-h transfection period, the EDEM1-
FLAG/Golgi-EGFP-expressing cells observed after
1 day were non-colony-forming, single cells (Fig. 1A).
Following 3 or 7 days in culture, the few remaining
EDEM1-FLAG/Golgi-EGFP-expressing cells were
non-colony-forming giant cells (Fig. 1B, C). The
HeLa cells expressing EDEM1-FLAG/Golgi-EGFP
were rounded and exhibited fragmented nuclei,
although more cells survived after 7 days in culture
compared to EDEM1-transfected HepG2 cells
(Fig. 1D–F). As in the case of HepG2 cells, the
EDEM1-FLAG/Golgi-EGFP-expressing HeLa cells
were only single, non-colony-forming cells. The con-
trols, HepG2 and HeLa cells transfected with
p3xFLAG-CMV vector/Golgi-EGFP showed no
signs of cytotoxicity up to 7 days after transfection
(Supplementary Fig. 1). HEK293 cells were least
sensitive to EDEM1 overexpression since, at 7 days
after transfection, EDEM1-expressing cells were
observed (Fig. 1G–I). In agreement with this obser-
vation, another group reported that EDEM1 over-
expression is not deleterious to HEK293 cells and
actually protects them against the action of ricin [10].
By semiquantitative RT-PCR, control HEK293 cells
contained about four times less EDEM1 mRNA
compared with HepG2 cells (Supplementary Fig. 2),
which may explain the differential sensitivity of these
cell lines to EDEM1 overexpression. Taken together,
uncontrolled expression of EDEM1 over a certain
level resulted in deleterious effects that blocked cell
division and caused apoptotic cell death in the cell
lines studied.
Influence of proteasome inhibition on degradation of
endogenous EDEM1. To clarify the role of protea-
somes in the degradation of endogenous EDEM1,
HepG2 cells were metabolically labeled with
[35S]cysteine/methionine and chased in the presence
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of various proteasome inhibitors (Fig. 2). All pulse-
chase experiments were performed under non-starva-
tion conditions to prevent unwanted starvation effects
such as induced proteasomal protein degradation [33]
or blockage of eIF4-dependent protein synthesis by
the induction of an unfolded protein response [34].
Clearance rates of proteins in pulse-chase experi-
ments can be accuratelymeasured by the estimation of
the slope of the degradation curve. The estimation of
the residual relative amount of the proteins present at
a given time and the calculation of half-lives are not as
reliable. Therefore, we calculated the EDEM1 clear-
ance rate per hour from at least three independent
experiments. The affinity-purified anti-EDEM1 pep-
tide antibodies used in our experiments reacted with
both glycosylated and deglycosylated forms of
EDEM1 with the expected molecular masses in
Western blots (Supplementary Fig. 3A). At the end
of a 30-min pulse, heterogeneously glycosylated forms
of EDEM1 (based on PNGase F sensitivity, Supple-
mentary Fig. 3B) and one not glycosylated EDEM1
form were immunoprecipitated (Fig. 2A), as previ-
ously observed in translation experiments in vitro
using a different EDEM1-specific antibody (Fig. 1B in
[14]). The immunoprecipitated and PNGase F degly-
cosylated EDEM1 from HepG2 cell lysates migrated
in 2-D gels at the calculated isoelectric points at 6.2
(asparagine formofEDEM1) and 5.8 (deglycosylated,
aspartate form of EDEM1) (Supplementary Fig. 3C).
Treatment with the proteasome inhibitors epoxomy-
cin or MG 132 (Fig. 2) as well as ALLN (not shown)
did not inhibit the clearance of glycosylated EDEM1
and only marginally inhibited clearance of deglycosy-
lated EDEM1 during the second hour of chase
(Fig. 2C). Actually, proteasome inhibition seemed to
enhance the clearing of glycosylated EDEM1 during
the first hour of chase (Fig. 2C). In our experiments,
we had to allow for the fact that the rate of
disappearance of the glycosylated EDEM1 reflects
its rate of de-glycosylation. This explains the higher
percentage of clearance of deglycosylated EDEM1
observed after 2-h treatment with proteasome inhib-
itors as compared to 1-h treatment (Fig. 2C). In
accordance, and in contrast to vinblastine (see
below), proteasome inhibitors did not affect the
clearance of intermediate glycosylated EDEM1
(Fig. 2C). The effectiveness of the proteasome inhib-
itors used in our experiments was verified simulta-
neously by Western blot for polyubiquitin. Accumu-
lation of polyubiquitinated proteins was already
significant after 1 h of treatment with proteasomal
inhibitors (Supplementary Fig. 4) and remained high
during the entire time period of proteasome inhib-
ition, as expected [35, 36]. Together, these data
demonstrated that the proteasome inhibitors used
did not stabilize endogenous EDEM1, indicating the
existence of another degradation pathway.
EDEM1 is degraded by autophagy. To explore the
possibility that autophagy is involved in the degrada-
tion of EDEM1, we used LC3A, the LC3 paralog
highly expressed in hepatocytes (http://www.unipro-
t.org/uniprot/Q9H492), as specific autophagosome
membrane marker [35, 36]. We observed endogenous
EDEM1 in autophagosomes of HepG2 cells under
basal conditions by double confocal immunofluores-
cence for endogenous LC3A and EDEM1 (Fig. 3A–
F, inset 1) and by immunogold electron microscopy
(Fig. 3G). In addition, we observedEDEM1 in LC3A-
and LAMP1-positive structures corresponding to
autophagolysosomes (Fig. 3A–F, inset 2) as well as
in LC3A-negative but LAMP1-positive structures
that correspond to lysosomes (Fig. 3A–F, inset 3).
Clearance of cytosolic proteins by autophagy has been
shown to correlate with their propensity to aggregate
[37–39]. We obtained evidence compatible with the
presence of aggregated cytosolic EDEM1 by detect-
ing both Triton X-100-soluble and Triton X-100-
insoluble EDEM1 (Fig. 4A). Of note, the Triton X-
100-insoluble EDEM1 was deglycosylated. Further-
more, by immunoelectron microscopy, clusters of
EDEM1 were observed that were partially or com-
pletely surrounded by double-membrane structures
typical of forming and of mature autophagosomes,
Figure 1. Overexpression of EDEM1 results in cytotoxicity.
HepG2 cells (A–C), HeLa cells (D–F) and HEK293 cells (G– I)
were simultaneously transiently transfected to express EDEM1-
FLAG (red) and as reporter proteinGolgi-targetedEGFP (green).
In all cell types, overexpressed EDEM1 (red) is distributed
throughout the cytoplasm, and in HepG2 cells results in giant cell
formation (C), and in HeLa cells in fragmentation of nuclei as
indication of apoptosis (E, F). HEK293 cells overexpressing
EDEM1 (G-I) as well as HepG2 and HeLa cells expressing only
Golgi-EGFP show undisturbed morphology. Nuclei are stained in
blue by Hoechst 33342. Bars, 10 mm.
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respectively (Figs. 4B and 3G), providing further
evidence of autophagy of cytosolic EDEM1 aggre-
gates.
Since the actual number of autophagosomes under
basal conditions is rather small in mammalian cells,
HepG2 cells were treated with vinblastine to block
their fusion with lysosomes and to increase their
number [40, 41]. By triple confocal immunofluores-
cence (Fig. 5A–D), we then observed numerous LC3-
positive structures throughout the cytoplasm (Fig. 5B)
and co-distribution of EDEM1 with numerous auto-
phagosomes (Fig. 5C, D). By serial section immuno-
peroxidase electron microscopy, groups of EDEM1-
containing typical autophagosomes were observed in
vinblastine-treated HepG2 cells (Fig. 5E, F and Sup-
plementary Fig. 5). In the same cells, both EDEM1-
positive autophagosomes (AP1 and AP2 in Fig. 5F)
and EDEM1-unreactive autophagosomes, which con-
tained fragments of ERprofiles (AP3 in Fig. 5F), were
noticed by immunoelectron microscopy. As an indi-
cation of successful inhibition of autophagosome-
lysosome fusion, vinblastine treatment in pulse-chase
experiments resulted in an increase of the autopha-
gosome membrane-anchored LC3A-II form (Supple-
mentary Fig. 6).
The presence of EDEM1 in autophagosomes was
independently verified biochemically by the detection
of EDEM1 immunoreactivity in LC3A immuno-
purified vesicles obtained from post-nuclear micro-
somal fractions (Fig. 5G). The sole LC3A form
detected in these purified vesicles was, as to be
expected [35], the membrane-bound LC3A-II form.
In OptiPrep gradients, immunoreactivity of glycosy-
lated and deglycosylated EDEM1 co-migrated with
LC3A-I, LC3A-II and LAMP1 membranes in light-
density fractions (Fig. 5H, fractions 2, 3). They were
separate from denser, calnexin-immunoreactive frac-
tions, containing ER membranes (Fig. 5H, fractions
4). The major EDEM1-containing light-density
fraction was associated with the autophagosome
Figure 2.Endogenous EDEM1 is
not degraded by proteasomes.
(A) Non-starved HepG2 cells
were pulsed for 20 min with
[35S]cysteine/methionine and
chased for the indicated times in
the absence (control) or presence
of epoxomycin or MG132. Im-
munoprecipitates prepared from
post-nuclear fractions of cell ly-
sates with anti-EDEM1 antibod-
ies were resolved by reducing
SDS-PAGE and subjected to au-
toradiography. (B) Densitometry
of residual EDEM1 at different
chase time points of the experi-
ment shown in (A) is presented.
(C) Clearance rate (percentage
of EDEM1 removed per hour) of
glycosylated (left) and deglyco-
sylated (right) EDEM1 was ob-
tained from three independent
experiments and its mean is
shown (glyco, glycosylated, de-
glyco, deglycosylated). Bars rep-
resent standard error of the
mean.
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membrane marker LC3A-II. It is therefore different
from the very dense EDEM1-containing fraction that
co-migrated with the insoluble, tubulin-associated
LC3-I form reported by others [17].
Next, the influence of vinblastine treatment on the
clearance of EDEM1 glyco-forms was analyzed in
pulse-chase experiments (Fig. 6). Vinblastine, but not
pepstatin/E64d, slightly delayed the clearance of the
glycosylated EDEM1 (Fig. 6A–C). De-glycosylation
of EDEM1 was delayed under vinblastine for about
1 h, as shown by the stabilization effect on the
intermediate glycosylated forms (arrowheads in
Fig. 6A). However, vinblastine had an immediate
strong inhibitory effect on the clearance of deglycosy-
lated EDEM1 (Fig. 6A–C). This stabilization effect
lasted for about 2 h. The effect of combined pepstatin
A/E64d treatment, inhibitors of major lysosomal
aspartic and cysteine proteases [42], on EDEM1 did
not last as long, probably due to the activities of other
lysosomal hydrolases. It delayed the clearance of the
deglycosylated EDEM1 during the first hour of chase
but not of the glycosylated one (Fig. 6A–C).
Figure 3. Endogenous EDEM1 is detected in autophagosomes. (A–F) HepG2 cells were triple labeled for endogenous EDEM1,
endogenous LC3 as marker for autophagosome membrane and endogenous LAMP1 as marker for lysosomes and analyzed by confocal
immunofluorescence microscopy. A single optical section through a HepG2 cell is shown. Higher magnification insets (1–3) show
examples of localization of EDEM1 in autophagosomes (insets 1), in phagolysosomes (insets 2), or in lysosomes (insets 3). Bar, 10 mm. (G)
Ultrathin frozen sections of HepG2 cells were immunogold-labeled for endogenous EDEM1 and show its presence in an autophagosome
(AP) with the typical double membrane. Bar, 125 nm.
Figure 4.EndogenousEDEM1 is found in aggregates anddelivered to autophagosomes. (A) ByWesternblot, EDEM1 is detected inTriton
X-100-soluble and -insoluble fractions of HepG2 cells. Both glycosylated and deglycosylated EDEM1 is detected in the Triton X-100-
soluble fraction, whereas only deglycosylated EDEM1 is detectable in Triton X-100-insoluble fraction. For the analysis of the insoluble
fraction, three times as muchmaterial as for the soluble fraction was loaded. (B, C) EDEM1 immunolabeling is detected inHepG2 cells as
clusters in the cytosol (arrow inB). Such clusters are partially (arrowhead in B) or completely surrounded by doublemembranes typical of
autophagosomes. Bars, 300 nm (A); 1 mm (B).
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Autophagosome formation can be inhibited either by
3-methyladenine [43] or by siRNA-mediated knock-
down of ATG5, ATG7, and ATG12 [28]. 3-Methyl-
adenine treatment stabilized the deglycosylated form
of EDEM1 (Supplementary Fig. 7A). Simultaneous
transfection of HepG2 cells with siRNAs for ATG5,
ATG7 and ATG12 for 48 h efficiently blocked the
formation of autophagosomes as indicated by the lack
ofATG5-ATG12 complexes and an increased amount
of the cytosolic form of LC3A-I (Fig. 6D). This
resulted in the accumulation of deglycosylated
EDEM1 in the Triton X-100-insoluble fraction, in-
dicating its aggregated state (Fig. 6D). Triton X-100-
insoluble EDEM1 was also observed in cells under
steady-state conditions (see Fig. 4A). In the Triton X-
100-soluble fraction, both glycosylated and deglyco-
sylated EDEM1 was found (Fig. 6D). Taken together,
both morphological and biochemical analysis indicat-
ed that endogenous EDEM1 under normal conditions
was degraded by basal autophagy.
Since we had previously observed EDEM1 in limited
portions of single ER cisternae [14], a serial section
analysis was performed to clarify whether these
EDEM1-containing ER cisternae were removed by
Figure 5.EndogenousEDEM1 is degradedby autophagy. (A–D)HepG2cellswere treatedwith vinblastine to enrich for autophagosomes.
Triple confocal immunofluorescence labeling for endogenousEDEM1, endogenousLC3 andendogenousLAMP1.A single optical section
through a HepG2 cell is shown. The insets illustrate the distribution of the three proteins at higher magnification and their distribution
relative to each other is shown in the overlay (D). Arrowhead in (D) points to a residual body. Bar, 10 mm. (E) Immunoperoxidase pre-
embedding labeling for EDEM1 in vinblastine-treated (30 min) HepG2 cells. Three serial ultrathin sections (#4, #6, #7) out of a larger
series (see Supplementary Fig. 5) demonstrateEDEM1 in a group of typical autophagosomes. Bar, 400 nm. (F) Three autophagosomes are
shown, two of which are positive for EDEM1 (AP1 and AP2). The autophagosome (AP3) containing ER profiles is not labeled for
EDEM1. Bar, 300 nm. (G) Autophagosomes were immuno-purified with LC3 antibody-coated magnetobeads from vinblastine-treated
HepG2 cells, resolved by reducing SDS-PAGE and subjected toWestern blot analysis for EDEM1 or LC3. Asterisk indicates heavy chain
of homologue Ig. (H) Post-nuclear cellular membranes from vinblastine-treated HepG2 cells were separated in a continuous 0–30%
OptiPrep gradient. Fractions in the order of increasing density were resolved on reducing SDS-PAGE and probed for calnexin (CNX),
LAMP1, EDEM1 and LC3. AP, Fractions containing autophagosomes/phagolysosomes.
Cell.Mol. Life Sci. Vol. 66, 2009 Research Article 1441
autophagy.However, EDEM1-containing ERwas not
observed in autophagosomes and, vice-versa,
EDEM1-positive autophagosomes did not contain
ER profiles (Fig. 7). This is in agreement of the
clearance of cytosolic EDEM1 clusters by autophagy
(Fig. 4B).
Discussion
The degradation pathway of ERAD substrates is well
known [3, 4], in contrast to the pathway taken by
machinery proteins of the protein quality control. In
the present study, we aimed to determine the degra-
dation pathway of the ERAD component EDEM1
under basal conditions in cells not stressed by the
overexpression of a transgenic misfolded glycopro-
tein. We observed that endogenous EDEM1 after exit
from the ER becomes deglycosylated, forms cytosolic
aggregates and is degraded by basal autophagy.
Furthermore, we obtained evidence that keeping
EDEM1 protein at endogenous levels is of physio-
logical importance, since uncontrolled overexpression
of EDEM1 evoked cytotoxic effects.
Our data show that overexpression of EDEM1 can
exert cytotoxic effects in cells not stressed by starva-
tion or by an overload with transgenic ERAD
substrates. Although the mechanism leading to
EDEM1 cytotoxicity is unclear at present, we propose
that the surplus of EDEM1 cannot be efficiently
removed by the steady-state ER-clearance mecha-
nism for EDEM1 [14]. The surplus EDEM1 present
throughout the ER is fully functional, as shown by the
accelerated release of overexpressed ERAD sub-
strates from calnexin and their clearance [8, 9].
However, in normal cells, this may result in an
indiscriminatory interaction of EDEM1 with all kind
of glycoproteins carrying mannose-trimmed N-gly-
cans and their retention in the ER lumen.
Figure 6. Endogenous EDEM1 is degraded by autophagy. (A) HepG2 cells were pulsed for 20 min with 35S-labeled methionine/cysteine
and chased for the indicated times in the absence (control) or presence of vinblastine or pepstatin A/E64d. Cell lysates were
immunoprecipitated with anti-EDEM1 antibodies, resolved by reducing SDS-PAGEand subjected to autoradiography. (B) Densitometry
of residual EDEM1 at different chase time points of the experiment shown in (A) is presented. (C) Clearance rate (percentage of EDEM1
removed per hour) of glycosylated (left) and deglycosylated (right) EDEM1 was obtained from three independent experiments and its
mean is shown. Bars represent standard error of the mean. (D) HepG2 cells were incubated with siRNA targeting mRNAs of ATG5,
ATG7, andATG12 for 48 h.Western blot analysis for EDEM1,ATG5-ATG12 complexes, GAPDHandLC3 of cell lysates fromTritonX-
100-soluble and -insoluble fractions is shown. As control, siRNA of a1-antitrypsin was used since this secretory protein is abundant in
HepG2 cells.
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None of the proteasome inhibitors used in our experi-
ments delayed the turnover of EDEM1, similar to that
reported for mouse fibroblasts treated with the
proteasome inhibitor PS-341 [17]. At least two
possible mechanisms can be envisaged in explanation.
We favor that EDEM1 is genuinely degraded by
autophagy since the inhibitors of the autophagy-
lysosome pathway acted not only efficiently but also
rapidly. Alternatively, proteasomal degradation could
be the inherent pathway of EDEM1 and its functional
blockade could be compensated for by autophagy.
However, we believe this not to be likely, since, in
ATG siRNA knockdown experiments combined with
proteasome inhibition by MG 132, no surplus Triton
X-100-insoluble EDEM1 was detected (Supplemen-
tary Fig. 7). We noticed that under the various
conditions applied for autophagy-lysosome inhibition,
EDEM1 was not fully stabilized. In fact, about 50%
was lost during the chase. This was due to the
formation of Triton X-100-insoluble cytosolic
EDEM1 aggregates. In agreement, EDEM1 aggre-
gates were detected in LC3-I-containing high-density
fractions of mouse embryonic fibroblasts [17]. Such
EDEM1-containing aggregates could not be immu-
noprecipitated since they were contained in the
nuclear fraction (unpublished data). This is probably
also the reason why EDEM1 became undetectable in
ATG5–/– cells [17]. The question then arises why the
EDEM1-containing aggregates are not deleterious in
autophagy-incompetent cells. In this regard, it has
been shown that accumulated protein aggregates
become distributed asymmetrically during mitosis to
one daughter cell, leaving the other free of accumu-
lated aggregates [44]. This would explain why au-
tophagy-incompetent cells like ATG5–/– cells can
survive in culture.
The majority of endogenous EDEM1 is found outside
the lumen of the ER under basal conditions and only
limited portions of a few ER cisternae contain
EDEM1 [14]. In the present electron microscopic
serial section analysis, no evidence for autophagic
removal of EDEM1-containing parts of the ER was
found. Thus, autophagy of EDEM1 comprises the
clearance of cytosolic EDEM1 aggregates and has to
be distinguished from the autophagy of ER cisternae
containing aggregated misfolded protein [45, 46], or
from ER-phagy, which is the selective autophagy of
surplus ER under non-steady state conditions [31, 47,
48]. There is other evidence that the autophagy-
lysosome system, but not proteasomes, are involved in
Figure 7.EDEM1 containing ER
cisternae are not subjected to
ER-phagy. Pre-embedding im-
munoperoxidase immunolabel-
ing for EDEM1. In this series of
consecutive ultrathin sections, an
EDEM1-labeled ER cisterna
(ER), which can be followed
through all sections and a nearby
EDEM1-labeled autophago-
some (AP) are observed. Bar,
850 nm.
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the degradation of proteins of the ER protein quality
control machinery. For instance, ER glucosidase II
was detected in autophagosomes [49], which seems to
be its degradation pathway [50]. Furthermore, degra-
dation of ER mannosidase I did not occur by
proteasomes but through lysosomal enzymes [51].
Proteins present in the cytosol may not become
degraded by proteasomes for simple sterical reason
since they must be unfolded before they can be
translocated into the proteolytic core of the protea-
some [52]. As a case in point, aggregate-prone
cytosolic proteins, which are a hallmark of chronic
neurodegenerative diseases, have been shown to be
preferentially degraded by autophagy [37–39]. More-
over, it has been shown that surplus single fibrinogen
chains are degraded by proteasomes, whereas surplus
dimeric fibrinogen chains are not [53–55]. EDEM1,
which exits the ER by a vesicular pathway [14],
apparently becomes deglycosylated in the cytosol and
forms detergent-insoluble aggregates. Further studies
are required to determine whether or not this takes
place in complex with the bound substrate. Likewise,
additional studies are needed to uncover the mecha-
nism by which EDEM1 becomes cytosolic and if the
membrane of the EDEM1 vesicles has to be disinte-
grated for this mechanism [56, 57].
In conclusion, our data demonstrate that endogenous
EDEM1 after its exit from the ER lumen is degraded
by basal autophagy. The present results also suggest
that EDEM1 is not recycled but undergoes degrada-
tion similar as the ERAD substrates themselves.
Electronic supplementary material. Supplementary material is
available in the online version of this article at springerlink.com
(DOI 10.1007/s00018-009-9038-1) and is accessible for authorized
users.
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